Cardiac repair therapy following heart attack
After suffering a heart attack (i.e. STEMI type), a single dose IGF-1 therapy is effective in decreasing the size of the dead heart tissue by at least 60%. Considering extensive use of stents in coronary angioplasty, eluting IGF1 from a stent is an ideal way to not only promote heart tis sue survival and repair, but also to prevent early stent restenosis (blockage) or delayed thrombosis ( blood clots), being the common side-effects associated with stenting. IGF1 delivered on a stent will thus add substantially to the current structural benefits of stent implantation in the STEMI setting. Moreover tissue repair will reduce the requirement for defibrillator implantation in a large number of patients whose heart function continues to deteriorate over the first two months following an attack. This stent will therefore provide a major cost saving for healthcare providers as well as health benefit in patients suffering heart attacks
Click here to read more.